A private placement of senior notes and Series S warrants involving Scopia Holdings has brought in $5 million for New York-based PAVmed. The company, which makes the PortIO intraosseous infusion system and the CarpX device for treating carpal tunnel syndrome, will use the proceeds for accelerating its growth plan and pipeline of products to commercialization.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.